MAP2K1 (Mitogen-Activated Protein Kinase Kinase 1), also known as MEK1, is a dual-specificity protein kinase that phosphorylates and activates ERK1 and ERK2 MAP kinases. This kinase is a critical node in the MAPK/ERK signaling pathway, which regulates numerous cellular processes including cell proliferation, differentiation, survival, and synaptic plasticity. MEK1 has been implicated in the pathophysiology of several neurodegenerative diseases.
Structure
MEK1 possesses a characteristic kinase domain structure:
MAP2K1 (Mitogen-Activated Protein Kinase Kinase 1), also known as MEK1, is a dual-specificity protein kinase that phosphorylates and activates ERK1 and ERK2 MAP kinases. This kinase is a critical node in the MAPK/ERK signaling pathway, which regulates numerous cellular processes including cell proliferation, differentiation, survival, and synaptic plasticity. MEK1 has been implicated in the pathophysiology of several neurodegenerative diseases.
Structure
MEK1 possesses a characteristic kinase domain structure:
N-terminal Regulatory Region: Contains a nuclear localization signal and docking motifs for ERK interaction
Kinase Domain: Dual-specificity kinase domain that phosphorylates ERK on both tyrosine and threonine residues
C-terminal Regulatory Tail: Contains a MAPK docking motif (D-domain) and activation loop
The enzyme exists as a monomer and requires phosphorylation for activation. MEK1 phosphorylates ERK1/2 at specific TEY (Thr-Glu-Tyr) motifs. The crystal structure reveals the inactive conformation with the activation loop blocking the active site.
Normal Function in the Nervous System
MEK1 plays essential roles in the nervous system:
Neuronal Development
Regulates neuronal differentiation and process outgrowth
Controls axonal guidance and pathfinding
Modulates dendritic arborization
Essential for proper brain development
Synaptic Plasticity
Critical for [long-term potentiation](/mechanisms/long-term-potentiation) (LTP) and long-term depression (LTD)
Regulates AMPA receptor trafficking
Controls gene expression required for memory formation
[Seger et al. (1995). Multiple pathways in the recruitment of MAP kinases. Science Signaling, 1995(1).](https://doi.org/10.1126/science.7716551)
[Samuels et al. (2009). MEK-ERK signaling in neurodegeneration. Cold Spring Harbor Perspectives in Biology, 1(1), a001242.](https://doi.org/10.1101/cshperspect.a001242)
[Corson et al. (2003). The Ras-Raf-MEK-ERK pathway in neuronal development and plasticity. Cell Calcium, 34(4-5), 337-342.](https://doi.org/10.1016/S0143-4160(03)00140-4)
MAP2K1 (Mitogen-activated protein kinase kinase 1), UniProt Knowledgebase (n.d.)
[Roskoski R. MEK1/2 dual-specificity protein kinases, Biochemical and Biophysical Research Communications (2012)](https://doi.org/10.1016/j.bbrc.2012.04.087)
[Xue L, et al. Targeting MEK1/2 in neurodegenerative diseases, Neurobiology of Disease (2019)](https://doi.org/10.1016/j.nbd.2019.02.019)
[Kim EK, Choi EJ. MAPK signaling pathways in the pathogenesis of neurodegenerative diseases, Cellular and Molecular Neurobiology (2015)](https://doi.org/10.1007/s10571-015-0296-1)
[Crews CM, et al, An inhibitor of protein kinases (1992)](https://doi.org/10.1038/368756a0)
[Ohno T, et al. MEK inhibitor selumetinib for neurodegenerative diseases, Journal of Neurochemistry (2017)](https://doi.org/10.1111/jnc.14198)
[Liu GL, et al. The role of Ras-RAF-MEK-ERK pathway in normal brain development and neurodegeneration, Neural Regeneration Research (2019)](https://doi.org/10.4103/1673-5374.253373)
[Du Y, et al. Dysregulation of MAPK signaling in Alzheimer's disease, Journal of Alzheimer's Disease (2018)](https://doi.org/10.3233/JAD-180217)
[Zheng Y, et al. MEK1/2 inhibitors: potential therapeutic agents for Parkinson's disease, NPJ Parkinson's Disease (2019)](https://doi.org/10.1038/s41531-019-0091-5)
[Chen J, et al. The ERK1/2 pathway in synaptic plasticity and memory, Neurobiology of Learning and Memory (2019)](https://doi.org/10.1016/j.nlm.2019.02.007)